How to Choose an API Exporter for Long-Term Contract Supply: A Buyer's Guide

Introduction: The First Order Is Easy. Year Three Is the Test.

A formulator finds an API supplier with a good quotation, a clean Certificate of Analysis and a sample that passes testing. The first three orders arrive on time. Then a raw-material shortage hits the supplier's region, a lead time stretches from four weeks to ten, and the formulator discovers that nobody agreed in advance how such a problem would be handled.

Long-term supply is not a larger version of a first order. It is a different purchase. The question changes from "can this supplier ship what I ordered?" to "will this supplier still meet my specification, my schedule and my regulatory needs in two years, and what will we both do when something goes wrong?"

Searches for the "best API exporter" tend to return directories and large manufacturers' own pages. They rarely answer that question. This guide explains how to evaluate an API exporter for long-term contract supply: what to assess, which agreements to put in place, how to manage continuity risk and how to avoid the common mistakes. It draws on ICH quality guidelines, FDA publications, an industry best-practices guide from APIC (the Active Pharmaceutical Ingredients Committee of Cefic) and Government of India data, with every source listed at the end.

1. What Long-Term Contract Supply Really Requires

A supplier that can sustain a long-term relationship has to deliver on three fronts at the same time. A weakness in any one of them eventually becomes a problem for the buyer.

• Quality that holds. The material meets the agreed specification batch after batch, and the supplier tells you before anything changes.
• Continuity of supply. The supplier can deliver the agreed volumes on the agreed schedule, and has a plan for disruption.
• Commercial terms that work for both sides. Forecasts, pricing, lead times and exit routes are written down, not assumed.

Why One Pillar Is Never Enough

A supplier with excellent quality but limited capacity cannot meet a growing forecast. A supplier with plenty of capacity but weak change control can alter a process without telling you. A supplier with both, but no written agreement, leaves you with nothing to rely on when a dispute arises. Evaluate all three, and ask for evidence of each.

2. Supplier Choice Is a Risk Decision, Not Only a Price Decision

For a regulated product, the responsibility for a purchased material stays with the company that buys it. ICH Q10, Pharmaceutical Quality System (Step 5, reference EMA/CHMP/ICH/214732/2007, legal effective date 1 June 2008 per EMA), makes this explicit in its section on outsourced activities and purchased materials. It states that "the pharmaceutical company is ultimately responsible to ensure processes are in place" to control such activities and materials, and it asks the company to:

• assess "the suitability and competence of the other party" before outsourcing operations or selecting material suppliers (section 2.7(a));
• set out responsibilities in a written agreement for outsourced activities (section 2.7(b));
• monitor and review the performance of the other party (section 2.7(c)); and
• monitor incoming ingredients and materials to ensure they come from approved sources (section 2.7(d)).

A Four-Phase Supplier Lifecycle

The APIC best-practices guide for managing suppliers of API manufacturers (Version 2, 18 March 2024, compiled by the Supplier Management Task Force of APIC, a sector group of Cefic) describes supplier management as a lifecycle in four phases. The guide is a best-practices document with no legal basis and no regulatory endorsement, and it is written for API manufacturers managing their own suppliers. Its structure still maps well onto a formulator managing an API supplier.

Risk Sets the Depth of Diligence

The APIC guide scales its requirements to the criticality of the material (high, medium or low). It states that on-site audits are the default for initial qualification, and that remote or paper audits are discouraged for new partners. It also notes that audits are not mandatory under GMP, that the quality unit has "the exclusive authority to approve or reject suppliers," and that audit outcomes are rated Acceptable, Conditionally acceptable or Unacceptable.

For a material that drives your product's quality or your ability to ship, treat the supplier as high criticality. For a lower-risk material, scale the effort to the risk, as the guide recommends.

3. A Scorecard for Evaluating an API Exporter

Use the scorecard below to compare candidates on the same terms. It turns "the best API exporter" from an opinion into a set of checks.

4. The Quality Agreement: What It Should Cover

A quality agreement is the written document that sets out who is responsible for what in a manufacturing relationship. FDA's guidance Contract Manufacturing Arrangements for Drugs: Quality Agreements (final, issued November 2016, docket FDA-2013-D-0558) says that parties "can use quality agreements to delineate their manufacturing activities to ensure compliance with CGMP." The guidance addresses contract drug manufacturing subject to current good manufacturing practice, so a bulk-ingredient purchase is not identical, but it is a useful model.

When It Is Needed

The APIC guide says quality agreements are mandatory for highly critical materials and services and are ideally signed before ordering begins. It adds that they should be reviewed periodically, and that if a supplier refuses or only partly accepts one, the risk assessment must be revisited.

What to Include

A quality agreement is not a substitute for a supply agreement. It covers quality responsibilities. The supply agreement covers volumes, price and delivery.

5. The Supply Agreement: Commercial Terms That Protect Both Sides

The terms below are general practice, not a legal template. Each one removes a point of friction before it becomes a dispute. Have your own legal advisers draft the contract.

Consolidating Several Materials With One Supplier

Many formulators buy more than one mineral ingredient. Moving several of them to one qualified supplier can reduce the number of audits, quality agreements and document sets to manage, and it simplifies forecasting. The trade-off is concentration risk: one supplier for everything is a single point of failure, so keep a qualified second source for critical materials.

6. Supply Continuity: Planning for Things Going Wrong

Score the Risk

The APIC guide bases its risk approach on ICH Q9 and calculates risk as probability multiplied by severity, using a 5 by 5 matrix. Its mitigation options include more testing, safety stock and alternative sources. Applied to an API supplier, the exercise asks: how likely is a disruption, and how serious would it be for you? A single-source material with a long lead time and no buffer scores high on both counts.

Three Practical Buffers

1. Safety stock. Hold enough inventory to cover the supplier's normal lead time plus a margin for delay.
2. A qualified second source. Qualify an alternative supplier while the first is performing, so a switch is a planned step and not an emergency.
3. Early-warning duty. Put a clause in the contract that obliges the supplier to tell you promptly about anything likely to affect supply.

Why Early Warning Matters for Regulated Products

Section 506C of the US Federal Food, Drug, and Cosmetic Act requires notification to FDA of a permanent discontinuance in manufacturing and of an interruption likely to lead to a meaningful disruption in supply. FDA's draft guidance on these notifications (Federal Register notice, 6 April 2023) addresses API manufacturing as well as finished products. The notice describes the respondents as applicants for approved NDAs, ANDAs and BLAs and manufacturers of certain unapproved prescription drugs. It also says notices for covered finished products should address whether an API is a reason for, or a risk factor in, a discontinuance or interruption, including the API's source and any known alternative sources.

In practical terms, a US-facing finished-product company that depends on an API can only meet that kind of obligation if its API supplier warns it early. FDA has since issued further draft guidance on the subject, so check the current status with FDA or your regulatory adviser.

Do Not Forget the Physical Chain

Continuity also depends on packaging, documentation and shipping. Agree pack sizes and labels in advance, confirm which export documents the supplier prepares routinely, and plan for customs clearance. Our guides on documents for customs clearance and on API import requirements by market cover these points.

7. Why Indian API Manufacturers Are Part of Many Long-Term Supply Plans

According to the Government of India's Press Information Bureau (PIB), in India's Pharmaceuticals in Global Healthcare: From Domestic Production to International Markets (21 March 2026):

• India ranks 3rd globally by volume and 11th by value in pharmaceuticals, and is "the largest global supplier of generic medicines, accounting for around 20 per cent of global supply."
• There are "about 500 active pharmaceutical ingredient (API) manufacturers, accounting for nearly 8 per cent of the global API industry."
• Pharma exports stood at USD 30.5 billion in 2024-25, reaching 191 countries.
• Under the Production Linked Incentive (PLI) scheme for bulk drugs, manufacturing capacity of 55,100 metric tonnes per year had been established for 26 critical APIs and key starting materials as of September 2025, with Rs. 4,763.34 crore of investment mobilised. PIB also reports that the PLI schemes for pharmaceuticals and bulk drugs together have avoided imports worth Rs. 3,591 crore.
• PIB describes the PLI scheme as aiming "to ensure a steady supply of critical inputs and reduce reliance on a single source."

What This Means for a Buyer

A deep supplier base gives a buyer choice and bargaining room. With about 500 manufacturers, though, quality systems vary widely. India's strength as a source is a reason to evaluate carefully, not a reason to skip evaluation.

8. From First Enquiry to Long-Term Contract: A Staged Approach

Most long-term relationships work best when they are built in stages, with evidence at each step.

1. Enquiry and document review. State the material, the specification, the end use and the destination market. Review the supplier's documents against the scorecard.
2. Samples and testing. Test samples against your specification, in your own laboratory or an independent one.
3. Qualification. Complete a questionnaire and, for critical materials, an audit.
4. Pilot orders. Place two or three orders under standard terms. Check batch consistency, lead times and documentation.
5. Agreements. Sign the quality agreement and the supply agreement, based on what the pilot orders showed.
6. Monitoring. Review supplier performance on a schedule, and re-evaluate after any change or quality event.

What a Pilot Phase Tells You

Three or four batches reveal things a sample cannot: whether results stay inside limits, whether documents arrive complete and on time, and how the supplier handles a small problem. A supplier that handles a small problem well is showing you how it will behave in a large one.

9. Shreeji Industries' Approach

Shreeji supplies formulators in more than 50 countries, and its minimum order quantity for Dried Ferrous Sulphate is 500 kg. Buyers interested in a recurring arrangement can discuss volumes, schedules and documentation needs with Shreeji's team directly, and can use the scorecard in this guide to ask for the evidence they need.

Where to Go Next

10. Common Misconceptions

Misconception 1: "The Best Exporter Is the One With the Lowest Price"

Price is one line in the total cost. A supplier that fails to deliver on schedule or changes a process without notice can cost far more than a small price difference saves.

Misconception 2: "A Good Sample Means a Good Supplier"

A sample shows that a supplier can make good material once. Long-term supply depends on batch-to-batch consistency, which only repeated batches can show.

Misconception 3: "A Certificate Proves the Supplier Is Reliable"

Certificates are evidence of a quality system at one point in time. Check the issuing body, scope and validity, and verify through audit where possible.

Misconception 4: "A Long-Term Contract Removes the Need for a Second Source"

A contract allocates responsibility. It does not prevent a plant shutdown. A qualified second source remains a standard risk control for critical materials.

Misconception 5: "Quality Agreements Are Only for Contract Manufacturers"

Any critical, long-term supply relationship benefits from a written statement of responsibilities. The APIC guide treats quality agreements as mandatory for highly critical materials and services.

11. Frequently Asked Questions

12. Sources and References

Data sourced from regulatory authority websites, government publications and, where noted, industry associations.